Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Hair follicle stem cells remain in bald individuals, but progenitor cells do not, raising questions about hair regrowth claims by Pelage. PP405 is discussed as a potential treatment, with skepticism about its effectiveness compared to existing treatments like Minoxidil and Finasteride.

Emerging hair loss treatments like PP405, a topical MPC inhibitor, show promise in activating stem cells for hair growth. The conversation seeks information on the development stages and accessibility of these treatments.

The user shared their 6-year journey using oral minoxidil 5mg, dutasteride 0.5mg daily, and dermarolling every 2.5 weeks at 1.5mm, experiencing significant hair regrowth despite initial shedding when switching brands. They attribute their success to a combination of treatments and emphasize the mental challenges faced during the process.

A 40-year-old man experiencing male pattern baldness reports noticeable hair regrowth after 6 weeks of using finasteride 1 mg daily, topical minoxidil 5% twice a day, and ketoconazole shampoo twice a week. He has not experienced any side effects and plans to continue monitoring his progress.

The user has been using Dutasteride, Minoxidil, microneedling, and Nizoral for 6 months and is seeking feedback on hair regrowth progress. A reply suggests growing out hair for better assessment.

The user is happy with their hair transplant done at age 21 to lower a naturally high hairline, despite minimal thinning. The conversation includes questions about the procedure details and assumptions about using finasteride.

A user is experiencing hair loss despite using topical minoxidil for 6 months and recently switching to foam, and is considering finasteride but is wary of side effects. Another user suggests continuing treatment and considering finasteride.

There is no new information on pp405, with data collection expected to finish by the end of 2025. Users are discussing the timeline for data analysis and completion of Pelage Pharmaceuticals' phase 2 study.

A user has been using finasteride and minoxidil for six months and is concerned about hair loss. Replies suggest continuing the treatment for at least a year, as initial shedding can indicate the treatment is working.

A new hair growth product claims to use apple stem cells, plant collagen, and bamboo leaf extract, with a 120-day money-back guarantee. Some users are skeptical, noting the product's marketing alongside other treatments like Minoxidil, finasteride, and red light therapy.

The conversation discusses hair loss treatments, specifically the use of oral minoxidil and finasteride over two years. Users inquire about dosages, shedding phases, and results, with some noting visible hair regrowth.

People are pessimistic about PP405, believed to be Jxl-069, due to doubts about its effectiveness and delivery method. Some think it doesn't work, while others blame the vehicle used for application.

A 26-year-old male experienced hair thinning since age 18 and tried various treatments, including topical minoxidil, oral finasteride, and a hair transplant. He is currently using topical finasteride, minoxidil, tretinoin, hydrocortisone, and oral dutasteride, and is satisfied with the results 6.5 months post-transplant.

A 29-year-old male shares his hair loss treatment progress using dutasteride, minoxidil, dermastamping, and ketoconazole shampoo, while discontinuing RU58841 due to side effects. He is hopeful for hair recovery to consider a hair transplant and discusses potential side effects and experiences with other users.

A 22-year-old shared their 6-month hair loss progress using only topical treatments like minoxidil, derma rolling, and red light therapy, without finasteride or oral medications. Other users suggested adding DHT blockers like RU58841 and ketoconazole shampoo for better results.

Pelage executives' hairlines were discussed, with speculation about them using PP405 for hair regrowth. Concerns were raised about using untested drugs, with some suggesting executives might not risk using them without safety data.

The user experienced significant hair regrowth after six months of using oral Finasteride (1mg) and Minoxidil (2.5mg) nightly, with no side effects. They also used dermastamping and biotin, emphasizing consistency and a healthy lifestyle.

The conversation is about using a topical spray containing minoxidil, finasteride, and tretinoin for hair regrowth over six months, with positive results and minimal side effects. The user also mentions using biotin and alpecin, and discusses the benefits of topical application over oral forms.

PP405 is expected to finish Phase 2 trials in late 2025, with potential market availability around 2028-2029 if all goes well. Current treatments like finasteride and minoxidil are still popular, while new options like KX-826 and Breezula are anticipated soon.

Setipiprant and Fevipiprant are questioned for their effectiveness in hair maintenance, with skepticism due to lack of convincing results beyond vellus hair growth. The user is satisfied with Minoxidil and Finasteride but is curious about the potential of DP2 inhibitors.

PP405 is discussed as a potential alternative to finasteride, but its effectiveness and market availability are uncertain. Users share experiences with finasteride, minoxidil, and topical treatments, noting side effects and application techniques.

PP405 is a potential new hair loss treatment that might replace finasteride and minoxidil, but it is still in clinical trials and may not be available until 2028-2031. There is skepticism about its effectiveness, with only a 20% increase in hair density observed in some participants.

Using finasteride and minoxidil for six months led to improved hair density and appearance. A temporary decrease in libido was noted as a side effect.

The user had high DHT levels after 8 months on dutasteride, questioning the drug's authenticity. They got dutasteride from a legitimate source and will update on progress.

The user improved hair health by using a topical spray with Minoxidil (7%) and Finasteride (0.3%), switching to Nizoral shampoo with 1% ketoconazole, and applying a multi-peptide serum for hair density. They emphasize the importance of maintaining a healthy scalp for effective hair regrowth.

A user is considering a hair transplant in a "mohawk" pattern with scalp micropigmentation (SMP) on the sides and back, questioning its feasibility and appearance. Others discuss donor region quality, potential scarring, and alternative treatments like dutasteride and RU58841.

A user is advocating for Phase 3 trials of the hair loss treatment PP405 to be conducted in Germany, citing benefits like a diverse patient base and faster access for European patients. Despite skepticism about the petition's influence, the user believes it can demonstrate significant interest and potentially influence strategic decisions.

Everychem's solution, similar to PP405, has mixed results for hair regrowth, with some users reporting improvements and others seeing no change or worsening hair loss. Users are sharing experiences and updates to determine its effectiveness.

Pelage plans to release phase 2 results and start phase 3 trials for PP405 in 2050, but skepticism remains due to past delays and unfulfilled promises. Users express frustration over the lack of progress in hair loss treatments, mentioning Minoxidil, finasteride, RU58841, CB-03-01, and Fluridil.

Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss, with excitement around a new drug, PP405, and a reformulated oral minoxidil in trials. Concerns about cost, side effects, and long-term use are also mentioned.